Company Description
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center.
Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Sean Nolan |
Contact Details
Address: 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247 United States | |
| Phone | 214 612 0000 |
| Website | tayshagtx.com |
Stock Details
| Ticker Symbol | TSHA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001806310 |
| CUSIP Number | 877619106 |
| ISIN Number | US8776191061 |
| Employer ID | 84-3199512 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sean P. Nolan | Chief Executive Officer and Chairman |
| Dr. Sukumar Nagendran M.D. | President, Head of Research and Development and Director |
| Kamran Alam CPA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Hayleigh Collins | Director of Corporate Communications and Investor Relations |
| Tracy M. Porter SPHR | Chief People Officer |
| Frederick Porter Ph.D. | Chief of Staff and Technical Operations Officer |
| Emily McGinnis M.P.H. | Chief Patient and External Affairs Officer |
| Sean McAuliffe | Chief Business Officer |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 3, 2025 | SCHEDULE 13G | Filing |
| Jun 3, 2025 | SCHEDULE 13D/A | Filing |
| Jun 3, 2025 | 8-K | Current Report |
| May 29, 2025 | 8-K | Current Report |
| May 29, 2025 | 424B5 | Filing |
| May 29, 2025 | 8-K/A | [Amend] Current report |
| May 28, 2025 | 424B5 | Filing |
| May 28, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |